SCHEMBL374061

SCHEMBL374061

COc1cc2c(Oc3ccc(NC(=O)O)cc3F)ccnc2cc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 2/20 0.63
MET P08581 13/20 0.62
AXL P30530 5/20 0.62
KDR P35968 5/20 0.62
FGFR2 P21802 1/20 0.58
FLT3 P36888 1/20 0.58
MERTK Q12866 1/20 0.58
AURKA O14965 1/20 0.58
JAK2 O60674 1/20 0.58
RPS6KA5 O75582 1/20 0.58
ABL1 P00519 1/20 0.58
INSR P06213 1/20 0.58
LCK P06239 1/20 0.58
RET P07949 1/20 0.58
IGF1R P08069 1/20 0.58
KIT P10721 1/20 0.58
PIM1 P11309 1/20 0.58
FGFR1 P11362 1/20 0.58
SRC P12931 1/20 0.58
PRKACA P17612 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12335711 0.90 MET (0.67) PDGFRAMETAXLKDRFLT3
SCHEMBL373942 0.87 FGFR2 (0.59) PDGFRAMETAXLKDRFGFR2
SCHEMBL19372993 0.87 FGFR2 (0.62) PDGFRAMETAXLKDRFGFR2
SCHEMBL22521192 0.86 FGFR2 (0.59) PDGFRAMETAXLKDRFGFR2
SCHEMBL16069968 0.86 MET (0.70) PDGFRAMETAXLKDRFGFR2
SCHEMBL2062881 0.86 MET (0.69) PDGFRAMETAXLKDRFGFR2
SCHEMBL373837 0.84 MET (0.64) PDGFRAMETAXLKDRFGFR2
SCHEMBL2744790 0.84 PDGFRA (0.69) PDGFRAMETAXLKDRFGFR2
SCHEMBL10243948 0.84 FGFR2 (0.59) PDGFRAMETAXLKDRFGFR2
SCHEMBL4401190 0.84 AXL (0.88) PDGFRAMETAXLKDRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408300-B1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO LTD (CN) 2016-05-11 EP disclosed
US-8232294-B2 Amino ester derivatives, sailts thereof and methods of use Xi, Ning (US) 2012-07-31 US disclosed
EP-2408300-A1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE Sunshine Lake Pharma Co., Ltd (CN) 2012-01-25 EP disclosed
WO-2010111063-A1 AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE XI NING (US) 2010-09-30 WO disclosed
US-20100239576-A1 AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239576-A1 AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE SRC, BCAT1, BCAT2 PDGFRA 423/4885MET 185/4885AXL 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.